Format

Send to

Choose Destination
J Ocul Pharmacol Ther. 2011 Dec;27(6):629-35. doi: 10.1089/jop.2010.0191. Epub 2011 Aug 10.

Palmitoylethanolamide effects on intraocular pressure after Nd:YAG laser iridotomy: an experimental clinical study.

Author information

1
Department of Cardiovascular, Respiratory, Nephrology and Geriatric Sciences, Centre Glaucoma and Ocular Electrophysiology, Sapienza University of Rome, Rome, Italy.

Abstract

PURPOSE:

The purpose of this article was to evaluate whether the anti-inflammatory agent palmitoylethanolamide (PEA) can counteract the increase of intraocular pressure (IOP) that may occur after neodymium-doped: yttrium aluminum garnet (Nd:YAG) laser iridotomy.

METHODS:

Fifteen patients underwent bilateral laser iridotomy (Visulas YAG III Laser; Zeiss) for the prevention of primary closed-angle glaucoma. The IOP was measured at the beginning of the study (t-1), after 15 days of pretreatment with placebo or PEA (t0), and at 15, 30, and 120 min after the iridotomy (t1, t2, t3). The pretreatment consisted of 2 tablets of placebo or PEA per day for 15 days.

RESULTS:

The t-test did not show a significant difference between the preoperative mean values of IOP t-1 and t0 in both the pretreatments. Analysis of variance/Tukey's test pointed out a significant increase of the postoperative IOP values in placebo pretreated patients (P≤0.05), but not in those who were pretreated with PEA. The trend analysis confirmed the significant positive trend in placebo pretreatment. The parallelism test between the 2 regressions showed a significant difference for the slopes (P=0.022) and not for the intercepts (P=0.520).

CONCLUSIONS:

PEA can counteract the increase of IOP that occurs after iridotomy. It is likely that PEA controls the inflammatory process after iridotomy.

PMID:
21830944
DOI:
10.1089/jop.2010.0191
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center